If might add to (and slightly correct) some items on your post:-...

If might add to (and slightly correct) some items on your post:
- there are 100s of bios with covid19 tests, but only a few that get TGA (AU) and USA FDA approval (to be secured this qtr) and that actually deliver reliable and 100% accurate serology test results.

- as per AT1's released test results, its one of a few only bios that has achieved 100% specificity in its results. example: UK Health just recalled 741k tests from a particular manufacturer (as a 'precaution' due to testing issues).

- AT1's device (including Access Bio vs BioTech test strips) do not require laboratory tests or additional reagents etc to produce a result. Its the only one of its all-in-one device that produces results within 15min. Several other bio tests require blood movement to the test device or reagents to be added manually or just don't reach 100% accurate result

- Atomo is not pursuing 'any bio who wants it' their device'. As JK has said previously, they don't wanna just partner up with anyone and are not looking for more - as it will cheapen their proposition and reputation. They have partnered ONLY with 2 companies to cover all regions globally. 2 partners who have developed best-in-class Covid19 test strips.

- in addition, Atomo also has distribution rights of the final Covid19 products (using BioTech strips) in SouthPacific, Philipines, Vietnam etc...so not just OEM $ but any $profit from the market RRP too.

- Atomo gets a % of the sales by Access Bio (subject to approvals for full device) across Americas, Sth Korea etc. % unspecified yet but that is significantly more % that just OEM wholesale price. And there are more than enough patients with Covid19 (sadly!) for this to circle the globe for several months, if not years yet.

- Atomo also gets its name known (via Access Bio's Covid19 releases) in USA, Sth America etc markets. This is no small deal for a company that makes devices that could be used for a variety of testing needs. HIV and malaria also are items that will need more focus in coming years.

All Atomo need to do is keep scaling up production, year on year...and their product will keep moving out the door (whether Covid19 or anything that needs a reputable, minimal risk test device). Every device they sell per month adds to bottom line & profit. And that's over their bread n butter HIV, malaria and other options already allocated from production.